Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study

Giulia Borgonovo, Elen Vettus, Alessandra Greco, Laura Anna Leo, Francesco Fulvio Faletra, Catherine Klersy, Moreno Curti, Mariacarla Valli, Giulia Borgonovo, Elen Vettus, Alessandra Greco, Laura Anna Leo, Francesco Fulvio Faletra, Catherine Klersy, Moreno Curti, Mariacarla Valli

Abstract

Background: The incidence of breast cancer is rising worldwide. Recent advances in systemic and local treatments have significantly improved survival rates of patients having early breast cancer. In the last decade, great attention has been paid to the prevention and early detection of cardiotoxicity induced by breast cancer treatments. Systemic therapy-related cardiac toxicities have been extensively studied. Radiotherapy, an essential component of breast cancer treatment, can also increase the risk of heart diseases. Consequently, it is important to balance the expected benefits of cancer treatment with cardiovascular risk and to identify strategies to prevent cardiotoxicity and improve long-term outcomes and quality of life for these patients.

Objective: This CardioTox Breast study aims to investigate the use of cardiac imaging, based on cardiac magnetic resonance and echocardiography, and to identify associated circulating biomarkers to assess early tissue changes in chemo-induced and radiation-induced cardiotoxicity in the time window of 12 months after the end of radiotherapy in patients with breast cancer.

Methods: The CardioTox Breast trial is a multicenter observational prospective longitudinal study. We aim to enroll 150 women with stage I-III unilateral breast cancer, treated with breast conserving surgery, who planned to receive radiotherapy with or without systemic therapy. Baseline and follow-up data include cardiac measurements based on cardiac magnetic resonance imaging, echocardiography, and circulating biomarkers of cardiac toxicity.

Results: This study details the protocol of the CardioTox Breast trial. Recruitment started in September 2020. The results of this study will not be published until data are mature for the final analysis of the primary study end point.

Conclusions: The CardioTox Breast study is designed to investigate the effects of systemic and radiation therapy on myocardial function and structure, thus providing additional evidence on whether cardiac magnetic resonance is the optimal screening imaging for cardiotoxicity.

Trial registration: ClinicalTrials.gov NCT04790266; https://ichgcp.net/clinical-trials-registry/NCT04790266.

International registered report identifier (irrid): DERR1-10.2196/31887.

Keywords: breast cancer; cardiac diagnostic imaging; cardiotoxicity; chemotherapy; radiotherapy.

Conflict of interest statement

Conflicts of Interest: None declared.

©Giulia Borgonovo, Elen Vettus, Alessandra Greco, Laura Anna Leo, Francesco Fulvio Faletra, Catherine Klersy, Moreno Curti, Mariacarla Valli. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 21.04.2022.

Figures

Figure 1
Figure 1
Protocol flow chart description. Blood: blood sample for circulating biomarkers; CMR: cardiac magnetic resonance; ECHO: echocardiography; RT: radiotherapy.

References

    1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019 Jan 22;321(3):288–300. doi: 10.1001/jama.2018.19323.2721183
    1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva Gulnar, Chen W, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP, CONCORD Working Group Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015 Mar 14;385(9972):977–1010. doi: 10.1016/S0140-6736(14)62038-9.S0140-6736(14)62038-9
    1. Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G, Bradley R, Brain E, Braybrooke J, Broet P, Bryant J, Burrett J, Cameron D, Clarke M, Coates A, Coleman R, Coombes RC, Correa C, Costantino J, Cuzick J, Danforth D, Davidson N, Davies C, Davies L, Di Leo A, Dodwell D, Dowsett M, Duane F, Evans V, Ewertz M, Fisher B, Forbes J, Ford L, Gazet J, Gelber R, Gettins L, Gianni L, Gnant M, Godwin J, Goldhirsch A, Goodwin P, Gray R, Hayes D, Hill C, Ingle J, Jagsi R, Jakesz R, James S, Janni W, Liu H, Liu Z, Lohrisch C, Loibl S, MacKinnon L, Makris A, Mamounas E, Mannu G, Martín M, Mathoulin S, Mauriac L, McGale P, McHugh T, Morris P, Mukai H, Norton L, Ohashi Y, Olivotto I, Paik S, Pan H, Peto R, Piccart M, Pierce L, Poortmans P, Powles T, Pritchard K, Ragaz J, Raina V, Ravdin P, Read S, Regan M, Robertson J, Rutgers E, Scholl S, Slamon D, Sölkner L, Sparano J, Steinberg S, Sutcliffe R, Swain S, Taylor C, Tutt A, Valagussa P, van de Velde C, van der Hage J, Viale G, von Minckwitz G, Wang Y, Wang Z, Wang X, Whelan T, Wilcken N, Winer E, Wolmark N, Wood W, Zambetti M, Zujewski JA. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology. 2018 Jan;19(1):27–39. doi: 10.1016/S1470-2045(17)30777-5.
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707–16. doi: 10.1016/S0140-6736(11)61629-2. S0140-6736(11)61629-2
    1. Barish R, Lynce F, Unger K, Barac A. Management of cardiovascular disease in women with breast cancer. Circulation. 2019 Feb 19;139(8):1110–1120. doi: 10.1161/CIRCULATIONAHA.118.039371.
    1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora Silvio, Noonan D. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010 Jan 06;102(1):14–25. doi: 10.1093/jnci/djp440. djp440
    1. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM, ICOS-ONE Study Investigators Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018 May;94:126–137. doi: 10.1016/j.ejca.2018.02.005.S0959-8049(18)30174-6
    1. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol. 2016 Mar;13(3):172–84. doi: 10.1038/nrclinonc.2015.171.nrclinonc.2015.171
    1. Pudil R. The future role of cardio-oncologists. Card Fail Rev. 2017;3(2):140–142. doi: 10.15420/cfr.2017:16:1.
    1. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F, ESMO Guidelines Working Group Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155–66. doi: 10.1093/annonc/mds293. S0923-7534(19)37674-4
    1. Zamorano JL, Lancellotti P, Rodriguez Muñoz Daniel, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016 Sep 21;37(36):2768–2801. doi: 10.1093/eurheartj/ehw211.ehw211
    1. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016 Jul 26;66(4):309–25. doi: 10.3322/caac.21341. doi: 10.3322/caac.21341.
    1. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 02;131(22):1981–8. doi: 10.1161/CIRCULATIONAHA.114.013777.CIRCULATIONAHA.114.013777
    1. Jacob S, Ferrières Jean. Breast cancer radiotherapy: A case of double jeopardy. Arch Cardiovasc Dis. 2016 Nov;109(11):587–590. doi: 10.1016/j.acvd.2016.09.001. S1875-2136(16)30151-6
    1. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen M, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987–998. doi: 10.1056/nejmoa1209825.
    1. Little MP, Tawn EJ, Tzoulaki I, Wakeford R, Hildebrandt G, Paris F, Tapio S, Elliott P. Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms. Radiat Environ Biophys. 2010 May 28;49(2):139–53. doi: 10.1007/s00411-009-0250-z.
    1. Cahlon O, Khan AJ. Cardiac toxicity: the more we learn, the less we know. Int J Radiat Oncol Biol Phys. 2017 Dec 01;99(5):1162–1165. doi: 10.1016/j.ijrobp.2017.08.048.S0360-3016(17)33845-2
    1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836–843. doi: 10.1056/nejm200003233421202.
    1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195–2207. doi: 10.1056/nejmoa0807646.
    1. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 Jan 27;391(10118):319–328. doi: 10.1016/S0140-6736(17)32814-3.S0140-6736(17)32814-3
    1. Onitilo AA, Engel JM, Stankowski RV, Liang Hong, Berg RL, Doi SAR. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012 Jul;134(1):291–8. doi: 10.1007/s10549-012-2039-z.
    1. Galderisi M, Lancellotti P. What Is The Best Imaging Tool In Cardio-oncology? European Society of Cardiology. 2019. Feb 20, [2022-01-10]. .
    1. Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, Ghez S, Georges J, Farhat H, Lambert J, Rousselot P, Livarek B. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. Eur Heart J Cardiovasc Imaging. 2017 Apr 01;18(4):392–401. doi: 10.1093/ehjci/jew223.jew223
    1. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy J, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P, International consensus group on cardiovascular magnetic resonance in myocarditis Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009 Apr 28;53(17):1475–87. doi: 10.1016/j.jacc.2009.02.007. S0735-1097(09)00496-3
    1. Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, Szilveszter B, Abbasi SA, Kwong RY, Scherrer-Crosbie M, Hoffmann U, Jerosch-Herold M, Neilan TG. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016 Dec;9(12):1–20. doi: 10.1161/CIRCIMAGING.115.003584. CIRCIMAGING.115.003584
    1. Galán-Arriola Carlos, Lobo M, Vílchez-Tschischke Jean Paul, López Gonzalo J, de Molina-Iracheta A, Pérez-Martínez Claudia, Agüero Jaume, Fernández-Jiménez Rodrigo, Martín-García Ana, Oliver E, Villena-Gutierrez R, Pizarro G, Sánchez Pedro L, Fuster V, Sánchez-González Javier, Ibanez B. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019 Feb 26;73(7):779–791. doi: 10.1016/j.jacc.2018.11.046. S0735-1097(18)39536-6
    1. Jordan JH, D’Agostino RB, Hamilton CA, Vasu S, Hall ME, Kitzman DW, Thohan V, Lawrence JA, Ellis LR, Lash TL, Hundley WG. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted vardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2014 Nov;7(6):872–879. doi: 10.1161/circimaging.114.002217.
    1. Walker V, Crijns A, Langendijk J, Spoor D, Vliegenthart R, Combs SE, Mayinger M, Eraso A, Guedea F, Fiuza M, Constantino S, Tamarat R, Laurier D, Ferrières Jean, Mousseaux E, Cardis E, Jacob S. Early detection of cardiovascular changes after radiotherapy for breast cancer: protocol for a European multicenter prospective cohort study (MEDIRAD EARLY HEART Study) JMIR Res Protoc. 2018 Oct 01;7(10):e178. doi: 10.2196/resprot.9906. v7i10e178

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren